Cardiff Oncology, Inc., a clinical-stage biotechnology company, develops drugs for the treatment of cancer. The company is headquartered in San Diego, California.
| Revenue (TTM) | 508,000 |
| Gross Profit (TTM) | $-34.82M |
| EBITDA | $-41.91M |
| Operating Margin | -9245.00% |
| Return on Equity | -94.10% |
| Return on Assets | -46.70% |
| Revenue/Share (TTM) | $0.01 |
| Book Value | $0.39 |
| Price-to-Book | 2.21 |
| Price-to-Sales (TTM) | 121.79 |
| EV/Revenue | 48.61 |
| EV/EBITDA | -3.66 |
| Quarterly Earnings Growth (YoY) | 0.00% |
| Quarterly Revenue Growth (YoY) | -14.10% |
| Shares Outstanding | $77.80M |
| Float | $75.38M |
| % Insiders | 6.20% |
| % Institutions | 21.88% |
Volatility is currently expanding
SAN DIEGO, Nov. 03, 2026 (GLOBE NEWSWIRE) -- Cardiff Oncology, Inc. (Nasdaq: CRDF), a clinical-stage biotechnology company leveraging PLK1 inhibition to develop novel therapies across a range of cancers, today announced that company management will present and participate in 1x1 investor meetings at the UBS Global Biopharma Conference on November 16-17, 2026.
SAN DIEGO, Oct. 27, 2026 (GLOBE NEWSWIRE) -- Cardiff Oncology, Inc. (Nasdaq: CRDF), a clinical-stage biotechnology company targeting RAS-mutated cancer by leveraging PLK1 inhibition, today announced the appointment of Leila Alland, MD, as interim Chief Medical Officer. Dr. Alland is a seasoned biopharmaceutical executive who has led multiple oncology drug development programs.
SAN DIEGO, Oct. 21, 2026 (GLOBE NEWSWIRE) -- Cardiff Oncology, Inc. (Nasdaq: CRDF), a clinical-stage biotechnology company leveraging PLK1 inhibition to develop novel cancer therapies, today announced that the U.S. Food and Drug Administration (FDA) has granted Orphan Drug Designation to onvansertib for the treatment of patients with chronic myelomonocytic leukemia (CMML). “CMML remains a difficult-to-treat hematologic malignancy with limited treatment options for patients, and 40-50% of myeloproliferative CMML1 patients harbor RAS-pathway mutations, which are associated with more aggressive disease,” said Mani Mohindru, PhD, President and Chief Executive Officer of Cardiff Oncology.
SAN DIEGO and NERVIANO, Italy, Sept. 14, 2026 (GLOBE NEWSWIRE) -- Cardiff Oncology, Inc. (NASDAQ: CRDF) ("Cardiff") and Nerviano Medical Sciences S.r.l.
SAN DIEGO, Sept. 02, 2026 (GLOBE NEWSWIRE) -- Cardiff Oncology, Inc. (Nasdaq: CRDF), a clinical-stage biotechnology company leveraging PLK1 inhibition to develop novel therapies across a range of cancers, today announced that Mani Mohindru, Ph.D. will participate in two upcoming conferences.
Positive Phase 2 CRDF-004 data presented in an oral session at ASCO support advancement of 30 mg onvansertib plus FOLFIRI/bevacizumab into planned registrational program for first-line RAS-mutated mCRC
SAN DIEGO, July 15, 2026 (GLOBE NEWSWIRE) -- Cardiff Oncology, Inc. (Nasdaq: CRDF) (the “Company”), a clinical-stage biotechnology company leveraging PLK1 inhibition to develop novel cancer therapies, today announced that it has entered into definitive agreements for the purchase and sale of an aggregate of 8,571,429 shares of its common stock and accompanying warrants to purchase up to an aggregate of 8,571,429 shares of its common stock, at a purchase price of $1.05 per share and accompanying warrant in a registered direct offering. In addition, certain members of the Company's officers and directors are participating in the offering and have entered into definitive agreements for the purchase and sale of an aggregate of 731,707 shares of the Company's common stock and accompanying warrants to purchase up to an aggregate of 731,707 shares of the Company's common stock, at a purchase price of $1.435 per share and accompanying warrant.
- The trial achieved its primary goal of selecting the efficacious and safe dose of onvansertib + standard-of-care (SoC) regimen for the registrational program -
SAN DIEGO, June 01, 2026 (GLOBE NEWSWIRE) -- Cardiff Oncology, Inc. (Nasdaq: CRDF), a clinical-stage biotechnology company leveraging PLK1 inhibition to develop novel therapies across a range of cancers, today announced that company management will present and participate in 1x1 investor meetings at the Jefferies Global Healthcare Conference on June 2-4, 2026.
Completed successful End-of-Phase 2 meeting with the FDA and selected onvansertib dose and chemotherapy regimen for planned Phase 3 trial
Tiblio connects your broker and runs your put-and-call-writing strategy for you — on CRDF and any ticker you trade — then tracks every position and per-strategy win rate.
